Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of stants whose importation is banned in Germany.
A federal judge overseeing a raft of cases filed against Johnson & Johnson’s DePuy Orthopaedics subsidiary over its Pinnacle hip implants orders the medical device company to provide compliance monitoring reports to the plaintiffs’ lawyers.
The hallowed emerging markets in Brazil, Russia, India and China aren’t generating the kind of growth once expected for healthcare companies, according to a Frost & Sullivan report.
The millions of dollars in fees that medical device companies pay for FDA review aren’t exempt from sequestration, meaning the agency may lack the resources to keep up with promises that it made to the industry in exchange for the funds.
Jurors in Washington state vote 10-2 for Intuitive Surgical in the first of many lawsuits over the company’s da Vinci robotic surgical system
2. Medical device tax: Theragenics’ rhetoric and the GOP’s repeal Catch-22
Theragenics’ (NYSE:TGX) uses its 1st-quarter earnings report to focus on the impact of the medical device tax and MassDevice.com publisher Brian Johnson considers whether the GOP’s desire to take down the Affordable Care Act all at once is getting in the way of repealing the levy.
The U.S. Supreme Court agrees to hear Medtronic’s appeal of a patent infringement loss to rival Boston Scientific over cardiac rhythm management technology.